Observational studyAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2019
Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies.
Observational study in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.Journal of the American Society of Nephrology : JASN · 2021Trial
- Advances in antibody-mediated rejection of renal allografts.Frontiers in immunology · 2026Review
- Friend or foe: assessing the value of animal models for facilitating clinical breakthroughs in complement research.The Journal of clinical investigation · 2025Review
- Complement in Antibody-Mediated Rejection of the Kidney Graft: From Pathophysiology to Clinical Practice.Journal of clinical medicine · 2025Review
- Pushing the Survival Bar Higher: Two Decades of Innovation in Lung Transplantation.Journal of clinical medicine · 2024Review
- Anti-HLA Class II Antibodies Are the Most Resistant to Desensitization in Crossmatch-positive Living-donor Kidney Transplantations: A Patient Series.Transplantation direct · 2024Article
- Antibody-Mediated Rejection in Lung Transplantation: Diagnosis and Therapeutic Armamentarium in a 21st Century Perspective.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Therapy in the Course of Kidney Graft Rejection-Implications for the Cardiovascular System-A Systematic Review.Life (Basel, Switzerland) · 2023Review
- Characteristics and management of thrombotic microangiopathy in kidney transplantation.Korean journal of transplantation · 2023Review
- A bibliometric and knowledge-map analysis of antibody-mediated rejection in kidney transplantation.Renal failure · 2023Article
- Novel insights in the clinical management of hyperimmune patients before and after transplantation.Current research in immunology · 2023Review
- Innovative immunosuppression in kidney transplantation: A challenge for unmet needs.World journal of transplantation · 2022Review
- Protection of transplants against antibody-mediated injuries: from xenotransplantation to allogeneic transplantation, mechanisms and therapeutic insights.Frontiers in immunology · 2022Review
- Differential Treatment Effects for Renal Transplant Recipients With DSA-Positive or DSA-Negative Antibody-Mediated Rejection.Frontiers in medicine · 2022Article
- C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates.Nature communications · 2021Article
- Chronic transplant glomerulopathy: New insights into pathogenesis.Clinical transplantation · 2021Review
- Approaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells.Frontiers in immunology · 2021Review
- Elevated Terminal C5b-9 Complement Complex 10 Weeks Post Kidney Transplantation Was Associated With Reduced Long-Term Patient and Kidney Graft Survival.Frontiers in immunology · 2021Article
- Current Desensitization Strategies in Heart Transplantation.Frontiers in immunology · 2021Review
- Current Approaches to Desensitization in Solid Organ Transplantation.Frontiers in immunology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
We aimed to determine the long-term outcomes of eculizumab-treated, positive crossmatch (+XM) kidney transplant recipients compared with +XM and age-matched negative crossmatch (-XM) controls. We performed an observational retrospective study and examined allograft survival, histologic findings, long-term B-cell flow cytometric XM (BFXM), and allograft-loss-associated factors. The mean (SD) posttransplant follow-up was 6.3 (2.5) years in the eculizumab group; 7.6 (3.5), +XM control group; 7.9 (2.5), -XM control group. The overall and death-censored allograft survival rates were similar in +XM groups (P = .73, P = .48) but reduced compared with -XM control patients (P < .001, P < .001). In the eculizumab-treated group, 57.9% (11/19) of the allografts had chronic antibody-mediated rejection, but death-censored allograft survival was 76.6%, 5 years; 75.4%, 7 years. Baseline IgG3 positivity and BFXM ≥300 were associated with allograft loss. C1q positivity was also associated with allograft loss but did not reach statistical significance. Donor-specific antibodies appeared to decrease in eculizumab-treated patients. After excluding patients with posttransplant plasmapheresis, 42.3% (9/21) had negative BFXMs; 31.8% (7/22), completely negative single-antigen beads 1 year posttransplant. Eculizumab-treated +XM patients had reduced allograft survival compared with -XM controls but similar survival to +XM controls. BFXM and complement-activating donor-specific antibodies (by IgG3 and C1q testing) may be used for risk stratification in +XM transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.